443 related articles for article (PubMed ID: 11418482)
1. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC
Blood; 2001 Jul; 98(1):210-6. PubMed ID: 11418482
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
Hayashi T; Hideshima T; Akiyama M; Podar K; Yasui H; Raje N; Kumar S; Chauhan D; Treon SP; Richardson P; Anderson KC
Br J Haematol; 2005 Jan; 128(2):192-203. PubMed ID: 15638853
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi NC; Treon SP; Anderson KC
Blood; 2002 Jun; 99(12):4525-30. PubMed ID: 12036884
[TBL] [Abstract][Full Text] [Related]
4. Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells.
Miyazato K; Tahara H; Hayakawa Y
Cancer Sci; 2020 Aug; 111(8):2770-2778. PubMed ID: 32573072
[TBL] [Abstract][Full Text] [Related]
5. One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
Besson L; Charrier E; Karlin L; Allatif O; Marçais A; Rouzaire P; Belmont L; Attal M; Lombard C; Salles G; Walzer T; Viel S
Front Immunol; 2018; 9():704. PubMed ID: 29706958
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Richardson PG; Schlossman RL; Weller E; Hideshima T; Mitsiades C; Davies F; LeBlanc R; Catley LP; Doss D; Kelly K; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo JJ; Chauhan D; Balinski K; Zeldis J; Anderson KC
Blood; 2002 Nov; 100(9):3063-7. PubMed ID: 12384400
[TBL] [Abstract][Full Text] [Related]
7. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.
Dmoszynska A; Podhorecka M; Manko J; Bojarska-Junak A; Rolinski J; Skomra D
Neoplasma; 2005; 52(2):175-81. PubMed ID: 15800717
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
9. Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.
D'Souza C; Prince HM; Neeson PJ
Front Immunol; 2021; 12():632399. PubMed ID: 33746969
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
Quach H; Ritchie D; Stewart AK; Neeson P; Harrison S; Smyth MJ; Prince HM
Leukemia; 2010 Jan; 24(1):22-32. PubMed ID: 19907437
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.
Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PP; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI
J Pharmacol Exp Ther; 2003 Jun; 305(3):1222-32. PubMed ID: 12649301
[TBL] [Abstract][Full Text] [Related]
13. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Reddy N; Hernandez-Ilizaliturri FJ; Deeb G; Roth M; Vaughn M; Knight J; Wallace P; Czuczman MS
Br J Haematol; 2008 Jan; 140(1):36-45. PubMed ID: 17995965
[TBL] [Abstract][Full Text] [Related]
15. [Positive immunoregulation of thalidomide on human peripheral blood mononuclear cell cultures].
Yang Y; Zhang WG; Chen YX; Cao XM; He AL; Yang HY; Tian W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1172-7. PubMed ID: 17204188
[TBL] [Abstract][Full Text] [Related]
16. The use of thalidomide in myeloma therapy as an effective anticancer drug.
Sze DM; Brown R; Yang S; Ho PJ; Gibson J; Joshua D
Curr Cancer Drug Targets; 2006 Jun; 6(4):325-31. PubMed ID: 16848723
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Görgün G; Calabrese E; Soydan E; Hideshima T; Perrone G; Bandi M; Cirstea D; Santo L; Hu Y; Tai YT; Nahar S; Mimura N; Fabre C; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Oct; 116(17):3227-37. PubMed ID: 20651070
[TBL] [Abstract][Full Text] [Related]
18. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
20. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]